Global Pediatric Regulations: An Overview

Abstract

The purpose of the present review is to summarize the current pediatric regulatory requirements and also the regulatory efforts that need to be taken for the potential benefits of safety and efficacy to the pediatric patients. The importance of pediatric regulations came into existence as adult physiological conditions differ from that of children; therefore, the same dosage regimen cannot be recommended for both. Children deviate from adults with respect to pharmacokinetic and pharmacodynamic characteristics, and hence the effect of the drug has to be reconfirmed for pediatrics. Drugs used in pediatric clinics are often considered as “therapeutic orphans” throughout the world as they are difficult to develop and are not provided with sufficient information. The number of clinical trials performed in children is not sufficient. At present, laws and regulations aimed at drug development in the pediatric field have not been focused significantly. There are different regulatory bodies that administrate the pediatric regulations for a particular region.

Keywords

pediatric regulation Pediatric Review Committee Pediatric Investigation Plan pediatric clinical study

Get full access to this article

View all access options for this article.

References

Mankar

Gholap

Zende

Dighe

. Drug Regulatory Agencies in India, USA, Europe and Japan—a review. Int J Inst Pharm Life Sci. 2014;4(2):288–297.

Sengar

Tripathy

. Pharmaceutical regulatory agencies and organizations around the world: scope and challenges in drug development. PharmaTutor. https://www.pharmatutor.org/articles/pharmaceutical-regulatory-agencies-and-organizations-around-world-scope-challenges-in-drug-development. Published 2018. Accessed October 4, 2018.

Clement

Hanenberg

Chin

WWL

. Pediatric oral drug delivery: challenges and solutions. Contract Pharma. https://www.contractpharma.com/issues/2018-05-01/view_features/pediatric-oral-drug-delivery-challenges-and-solutions/5336. Published 2018. Accessed October 4, 2018.

Turner

Catapano

Hirschfeld

Giaquinto

. Paediatric drug development: the impact of evolving regulations. Adv Drug Deliv Rev. 2014;73:2–13.

Califf

. Best Pharmaceuticals for Children Act and Pediatric Research Equity Act: status report to Congress. Department of Health and Human Services, Food and Drug Administration. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/. Published 2016. Accessed October 4, 2018.

Roberts

Rodriguez

Murphy

Crescenzi

. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. J Am Med Assoc. 2003;290(7):905–911.

Zisowsky

Krause

Dingemanse

. Drug development for pediatric populations: regulatory aspects. Pharmaceutics. 2010;2(4):364–388.

Hathaway

Manthei

Scherer

. Exclusivity strategies in the United States and European Union. FDLI. https://www.lw.com/upload/pubcontent/_pdf/pub2655_1.pdf. Published 2009. Accessed October 4, 2018.

Ren

Zajicek

. Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: what can the obstetric community learn from the pediatric experience? Semin Perinatol. 2015;39(7):530–531.

10.

USFDA. Food and Drug Administration Safety and Innovation Act (FDASIA). https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/SignificantAmendmentstotheFDCAct/FDASIA/default.htm. Published 2018. Accessed October 4, 2018.

11.

USFDA. Food and Drug Administration Modernization Act (FDAMA) of 1997. https://www.fda.gov/regulatoryinformation/lawsenforcedbyfda/significantamendmentstothefdcact/fdama/default.htm. Published 2018. Accessed October 5, 2018.

12.

USFDA. Best Pharmaceuticals for Children Act (BPCA). https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm607936.htm. Published 2018. Accessed October 4, 2018.

13.

USFDA. Pediatric Research Equity Act (PREA). https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm607938.htm. Published 2018. Accessed October 6, 2018.

14.

USFDA. PREA vs. BPCA. https://www.accessdata.fda.gov/scripts/cderworld/index.cfm?action=newdrugs:main&unit=4&lesson=1&topic=8. Published 2018. Accessed October 5, 2018.

15.

USFDA. Pediatric Review Committee (PeRC). https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm607942.htm. Published 2018. Accessed October 4, 2018.

16.

Karesh

. Pediatric drug development: regulatory expectations. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/UCM407891.pdf. Published 2012. Accessed October 5, 2018.

17.

Bourgeois

Hwang

. The Pediatric Research Equity Act moves into adolescence. J Am Med Assoc. 2017;317(3):259–260.

18.

European Medicines Agency. Guideline on pharmaceutical development of medicines for paediatric use. European Medicines Agency. https://www.ema.europa.eu/documents/scientific-guideline/guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf. Published 2013. Accessed October 4, 2018.

19.

Smit-Marshall

Practical Paediatrics. Samedan Ltd. http://www.samedanltd.com/magazine/13/issue/142/article/2785. Published 2010. Accessed October 4, 2018.

20.

European Medicines Agency. ICH E11(R1) guideline on clinical investigation of medicinal products in the pediatric population. https://www.ema.europa.eu/documents/scientific-guideline/ich-e11r1-guideline-clinical-investigation-medicinal-products-pediatric-population-revision-1_en.pdf. Published 2017. Accessed October 4, 2018.

21.

European Medicines Agency. Paediatric Committee (PDCO). https://www.ema.europa.eu/en/committees/paediatric-committee-pdco. Published 2010. Accessed October 4, 2018.

22.

European Medicines Agency. Pediatric Investigation Plans. https://www.ema.europa.eu/en/human-regulatory/research-development/paediatric-medicines/paediatric-investigation-plans. Published 2006. Accessed October 3, 2018.

23.

The European Parliament and the Council of the European Union. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. The European Parliament and the Council of the European Union. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf. Published 2006. Accessed October 4, 2018.

24.

Kishore

Tabor

. EU regulations for clinical studies in pediatric patients. Regul Focus. 2010;15(11):39–44.

25.

EMEA. The Paediatric Regulation. https://www.ema.europa.eu/documents/presentation/presentation-paediatric-regulation_en.pdf. Published 2007. Accessed October 5, 2018.

26.

European Medicines Agency. Report on second workshop of the European Paediatric Research Network (EnprEMA), 16 March 2010. https://www.ema.europa.eu/documents/report/report-second-workshop-european-paediatric-research-network-enprema_en.pdf. Published 2010. Accessed October 5, 2018.

27.

Iwata-Okada

. Development of pediatric drugs in Japan: regulatory viewpoints. https://www.pmda.go.jp/files/000216529.pdf. Published 2015. Accessed October 5, 2018.

28.

SA Health. Paediatric clinical practice guidelines. https://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/clinical+resources/clinical+topics/paediatric+clinical+guidelines. Published 2012. Accessed October 4, 2018.

29.

Canadian Paediatric Society. Strategic Framework, 2017-2022. https://www.cps.ca/en/about-apropos/strategic-framework. Published 2018. Accessed October 5, 2018.

30.

Venkatesh

. Regulation for paediatric drug development in India: need of the hour. J Clin Stud. 2014;6(1):14–17.